

17 December 2024

Treatment of Prostate and Bladder Cancers

PROSTATE CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	10
1.2 Apalutamide (Erleada)	<5
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5 (+Prednisolone 10)
1.4 Darolutamide (Nubeqa)	<5
1.5 Enzalutamide (Xtandi)	27

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	<5 (+Darolutamide <5) (+Prednisolone <5)
2.2 Olaparib (Lynparza) for prostate cancer	<5
2.3 Talazoparib (Talzenna) for prostate cancer	<5

17 December 2024

Q3. How many patients were treated with the following combinations in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT	<5
3.2 Olaparib (Lynparza) + Abiraterone	<5

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
4.1 Abiraterone	Information not held
4.2 Enzalutamide	Information not held

BLADDER CANCER

Q5. How many patients were treated for bladder cancer (ICD-10 code = C67*) with the following products in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Atezolizumab (Tecentriq)	<5
5.2 Avelumab (Bavencio)	<5
5.3 Erdafitinib (Balversa)	<5
5.4 Nivolumab (Opdivo)	<5
5.5 Pembrolizumab (Keytruda)	<5

17 December 2024

Q6. Of the patients treated with nivolumab (Opdivo) for bladder cancer, how many were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Combination, monotherapy, adjuvant	Number patients treated
6.1 Nivolumab in combination with cisplatin and gemcitabine	<5
6.2 Nivolumab monotherapy as adjuvant treatment	<5
6.3 Nivolumab monotherapy in total	<5

ATEZOLIZUMAB (TECENTRIQ)

Q7. How many patients were treated with atezolizumab (Tecentriq) for the following cancer types in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Cancer type	Number patients treated
7.1 Lung Cancer	5
7.2 Breast Cancer	<5
7.3 Hepatocellular Carcinoma	5

Q8. How many of the patients treated with atezolizumab were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Combination, monotherapy, adjuvant	Number patients treated
8.1 Atezolizumab in combination with carboplatin and etoposide	<5
8.2 Atezolizumab as adjuvant treatment	Information not held
8.3 Atezolizumab in combination with bevacizumab, carboplatin and paclitaxel	<5